Hospitals and universities repurposing drugs at lower cost
Hospitals, universities, and nonprofits are increasingly exploring how existing drugs can be repurposed for new conditions at far lower cost, often after patents expire. Commenters highlight how off-label prescribing is already widespread but constrained by regulatory pathways, patent law, and insurance incentives that favor expensive, branded or newly patented variants over cheap generics. The thread also surfaces broader structural issues in U.S. healthcare—such as high drug prices, insurer profit rules, and the role of government vs. private R&D—in determining which treatments become accessible despite promising evidence.
How patients find repurposing studies
- Similar channels as other clinical trials: big health systems’ or universities’ mailing lists, public trial registries (e.g., clinicaltrials.gov), and disease‑specific patient communities.
- Specialists often know emerging evidence first and may suggest off‑label options.
- Some participants report positive experiences in clinical trials.
Regulation, patents, and off‑label use
- Off‑label prescribing is described as extremely common, especially for complex or rare conditions.
- Disagreement over whether new uses of old drugs can be patented; some say yes (with legal citations), others say it’s hard or not possible in practice.
- In the US, anyone can in principle file a new drug application for an existing compound, but practical control over manufacturing usually requires involvement of or becoming a manufacturer.
- In the UK, doctors can prescribe unlicensed uses, but official care “pathways” and liability issues matter.
- FDA’s process is seen as optimized for initial indication approval, not for systematically updating labels for new uses.
Insurance coverage and incentives
- Conflicting claims on whether insurers “typically” refuse to cover off‑label use; multiple commenters say coverage is routine, sometimes with prior authorization, especially for cheaper drugs.
- Others note insurers are not required to cover off‑label use, and coverage can be difficult for expensive treatments.
- Some argue US insurers have perverse incentives: medical loss ratio rules mean higher care costs can translate into higher absolute profits.
- Self‑insured employers and public programs (Medicare, Medicaid, VA, etc.) may have different incentives, but their reach is debated.
Examples of repurposed or off‑label drugs
- Low‑dose naltrexone (LDN) used off‑label (e.g., for ME/CFS, Long COVID); several users report substantial benefit.
- Gabapentin, approved for seizures, widely used off‑label for neuropathic pain.
- Esketamine (Spravato) vs generic ketamine for depression: same basic molecule family, but esketamine is patented, FDA‑approved, and vastly more expensive; some claim ketamine is more effective yet harder to get covered.
- Bevacizumab (Avastin) vs Lucentis for macular degeneration: similar targeting; Avastin is much cheaper but must be repackaged by compounding pharmacies, raising contamination risk. Past compounding disasters are cited.
- Cancer drugs and other existing agents are being trialed for blindness, Huntington’s disease, and other conditions via nonprofits and academic centers.
Drug pricing, markets, and capitalism
- US brand‑name drug prices are seen as driven by patent‑backed monopolies; generics are noted as relatively cheap.
- Debate over whether the US is “maximally capitalist” or better described as a regulated, monopoly‑friendly system.
- Some argue monopolies and patent law are anti‑competitive; others note patents are a deliberate tradeoff to force disclosure instead of trade secrets.
- There is discussion of prize models, “open‑sourcing” taxpayer‑funded drug discoveries, and government‑run, transparent clinical trials to break monopoly control.
Role of government vs private sector
- One side: government must fund baseline research and trials; unregulated markets (e.g., supplements) show how bad quality can be.
- Other side: skepticism that government programs stay efficient; risk of bureaucracy and political incentives distorting priorities.
- General agreement that current incentives (FDA risk‑aversion, pharma profit motives, insurance structures) make repurposing underused relative to its potential.
Benefits and limits of repurposing
- Repurposing is seen as powerful for rare diseases and for cheaper symptom control.
- Commenters stress it cannot replace new drug development, especially for conditions like some forms of Long COVID and ME/CFS, where no effective repurposed options have emerged.
- Several note that repurposing is most pursued once patents expire, often by universities and hospitals with limited commercial incentive.